Award Photo CVM  

Advancing the health and well-being of animals and people


Principal Investigator:  Richard Cerione

Department of Molecular Medicine
Contact Information:  Email: rac1@cornell.edu; Phone: 607-253-3888
Sponsor:  NIH-National Institute of General Medical Sciences (NIGMS)
Grant Number:  2 R01 GM047458-21
Title:  Roles of Cdc42 and its Signaling Partners in Cell Growth and Differentiation
Annual Direct Cost:  $198,000
Project Period:  05/01/2012-04/30/2016

DESCRIPTION (provided by applicant):  The small GTPase Cdc42 is highly conserved from yeast to humans and mediates a number of fundamentally important cellular processes including the establishment of cell polarity, the regulation of cell morphogenesis, and the control of cell growth and differentiation. In past funding periods, we have used a combination of biochemical, cell biological and structural approaches to gain insights into how Cdc42 impacts EGF receptor-signaling and influences cell growth, as well as how it affects cell migration, and cellular differentiation. More recently, we have been combining these approaches with the conditional knock-out of Cdc42 in mice, and the use of small molecules to probe its cellular and biological responses, which has led us to make some surprising new discoveries. In particular, we found that the two highly similar splice-variant forms of Cdc42, one that is ubiquitously distributed and the other that is brain specific, have distinct functions in neurogenesis, with the ubiquitous form of Cdc42 stimulating the transition of multi-potent embryonic cells to neuroprogenitors, while the brain-specific protein (Cdc42b) is necessary for their differentiation into neurons and glial cells. An important reason for these distinct functions is the unique ability of the ubiquitous form of Cdc42 to activate mTORC1. Moreover, we discovered that Cdc42, through its ability to signal to mTORC1, also regulates glutamine metabolism in the mitochondria, which has significant consequences for the “glutamine addiction” of cancer cells. Thus, in the coming project period we plan to build on these new findings to address three fundamentally important questions. 1) How is Cdc42 localized at the appropriate cellular sites to propagate signals that are important for cell growth and development?  We are especially interested in determining the molecular basis by which Cdc42 versus Cdc42b localize to their specific membrane sites to trigger different signaling outcomes. 2) Define the signaling pathway used by the ubiquitous form of Cdc42 and how it accounts for the functional specificity exhibited by Cdc42 versus Cdc42b. In particular, we will set out to learn how Cdc42 signals to mTORC1 and what is unique about its signaling partners versus those used by Cdc42b to initiate terminal differentiation. 3) How does Cdc42 influence cellular metabolism and thereby impact processes important both to cancer progression and neural development. We want to better understand how Cdc42 works through mTORC1 and NFКB to influence glutamine metabolism and the metabolic reprogramming critical for malignant transformation, as well as see whether there are similarities that extend to the role of Cdc42 in the formation of neuroprogenitor cells. These studies should provide important new insights into the roles of Cdc42/Cdc42b in normal cellular and biological processes, as well as how malfunctions in their signaling capabilities can contribute to a variety of disease states and developmental disorders.